About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

  • Sailormen Inc. Popeyes Raises More Than $1,000,000 for MDA

    The annual “Appetite for a Cure” program and golf tournament will help fund vital research and care for kids and adults affected by neuromuscular disease.

  • MDA and ALS ONE Form New Partnership to Accelerate ALS Biomarker Research

    MDA research grant awarded to ALS ONE will fund exploration of Positron Emission Tomography (PET) imaging of inflammation in people with ALS

  • MDA Awards $2.6 Million in New Research Grants

    Investment funds critical infrastructure, feeds a rapidly expanding therapy development pipeline and encourages researchers and other stakeholders to commit to the neuromuscular field

  • Target ALS Launches Biomarker Study with Academic, Industry, and Philanthropic Partners

    Unprecedented Effort Aims to Accelerate Testing of New ALS Therapies

    NEW YORK CITY, N.Y. ( April 19, 2018 ) — Target ALS today announced the launch of a new study that connects the CReATe Consortium (Clinical Research in ALS and Related Disorders for Therapeutic Development), the Muscular Dystrophy Association and 10 pharmaceutical companies to validate the most promising ALS biomarker candidates, and immediately make all results broadly available to the worldwide ALS research community.

  • MDA Names Michael J. Kennedy as Chief Financial Officer

    CHICAGO, March 30, 2018 — After a comprehensive nationwide search, the Muscular Dystrophy Association has announced the appointment of Michael Kennedy as Executive Vice President and Chief Financial Officer, effective March 19, 2018. Kennedy succeeds Julie Faber, who left MDA earlier this year.

  • Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy

    Cambridge, MA, March 14, 2018 – Solid Biosciences Inc. (NASDAQ: SLDB) today announced it has received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.